Neuroendocrine Neoplasm Clinical Trials

34 clinical trials for Neuroendocrine Neoplasm across international registries, including 11 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors — RECRUITING · PHASE1
• Project: Every Child for Younger Patients With Cancer — RECRUITING
• A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens — RECRUITING · PHASE1
• Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) — RECRUITING
• Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) — RECRUITING · PHASE2
• Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial — RECRUITING · PHASE2
• EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine Neoplasms — RECRUITING
• Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients — RECRUITING · PHASE2
• Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors — RECRUITING
• Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients — RECRUITING
• YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs. — RECRUITING
• Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors — ACTIVE_NOT_RECRUITING · PHASE3
• Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of PM8002 in Combination With Chemotherapy in Patients With NEN — ACTIVE_NOT_RECRUITING · PHASE2
• Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms — NOT_YET_RECRUITING · PHASE2
• Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer — COMPLETED · PHASE1
• Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases — ACTIVE_NOT_RECRUITING · PHASE2
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction — COMPLETED · PHASE1
• Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. — COMPLETED · PHASE2
• Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients — OTHER
• Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors — COMPLETED · PHASE2
• Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging — OTHER · PHASE1
• Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm — OTHER · PHASE2
• Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm — OTHER
• Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis — OTHER
• 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors — TERMINATED · PHASE1
• Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET) — OTHER
• A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors — OTHER · PHASE1
• A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms — OTHER · PHASE1
• Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor — WITHDRAWN · PHASE1

Refine this search